In what has become a near-weekly occurrence for the embattled New Jersey-based pharmaceutical company, Johnson & Johnson announced this week that it was recalling lots of four different drugs. On February 15th, J&J recalled antipsychotic Invega (due to possible contamination and risk of infections as well as sub-potency in some formulations), which has already been linked to at least one adverse event. On February 17th, J&J recalled Dermabond (poor manufacturing; inferior color quality) and Securestrap (product and packaging sterility problems). On February 18th, J&J recalled a number of lots of RA drug Simponi (injection pens may deliver sub-potent product dose).
Previously, the company has tried to contain the PR damage to just its McNeil division and only its Fort Washington, Pennsylvania facility. However, the current batch of recalls show the manufacturing lapses stretch around the world – from Fort Washington to Switzerland and places in between – as well as impact many different J&J divisions. The problems with J&J are systemic and widespread.